Patents by Inventor Katherine Ann Vousden

Katherine Ann Vousden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
    Publication number: 20240287192
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Application
    Filed: July 11, 2023
    Publication date: August 29, 2024
    Inventors: Katherine Ann VOUSDEN, Bo CHEN, Gary Patrick SIMS
  • TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20240199761
    Abstract: Antibodies for binding PADs and their use in therapy.
    Type: Application
    Filed: December 18, 2023
    Publication date: June 20, 2024
    Inventors: Gary SIMS, Catherine Eugenie HUNTINGTON, Katherine Ann VOUSDEN
  • Binding molecules specific for Fc?RIIA and uses thereof
    Patent number: 11746153
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: September 5, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME
    Publication number: 20230250167
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Inventors: Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
  • ILT7 binding molecules and methods of using the same
    Patent number: 11673950
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Julie Ann Douthwaite, Melissa Marie Damschroder, Miguel Angel Sanjuan
  • BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
    Publication number: 20220380458
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 1, 2022
    Applicant: VIELA BIO, INC.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME
    Publication number: 20220144940
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Application
    Filed: June 17, 2021
    Publication date: May 12, 2022
    Inventors: Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
  • Binding molecules specific for Fc?RIIA and uses thereof
    Patent number: 11306145
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: April 19, 2022
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • ILT7 binding molecules and methods of using the same
    Patent number: 11072652
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 27, 2021
    Assignee: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Julie Ann Douthwaite, Melissa Marie Damschroder, Miguel Angel Sanjuan
  • ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME
    Publication number: 20200339673
    Abstract: The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
    Type: Application
    Filed: March 9, 2017
    Publication date: October 29, 2020
    Applicant: Viela Bio, Inc
    Inventors: Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
  • BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
    Publication number: 20200002415
    Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: January 2, 2020
    Applicant: Viela Bio, Inc.
    Inventors: Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
  • Methods of Treatment Using CCA1 Inhibitors
    Publication number: 20120135453
    Abstract: Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor.
    Type: Application
    Filed: May 26, 2011
    Publication date: May 31, 2012
    Applicant: UCB Pharma SA
    Inventor: Katherine Ann Vousden
  • Methods of Treatment Using CCA1 Inhibitors
    Publication number: 20090209498
    Abstract: Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor.
    Type: Application
    Filed: February 23, 2009
    Publication date: August 20, 2009
    Applicant: UCB Pharma SA
    Inventor: Katherine Ann Vousden